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Amyloids are protein fibrils of nanometer size
resulting from protein self-assembly. They have
been shown to be associated with a wide variety
of diseases such as Alzheimer’s and Parkinson’s
and may contribute to various other pathological
conditions, known as amyloidoses. Insulin is prone
to form amyloid fibrils under slightly destabilizing
conditions in vitro and may form amyloid struc-
tures when subcutaneously injected into patients
with diabetes. There is a great deal of interest in
developing novel small molecule inhibitors of amy-
loidogenic processes, as potential therapeutic
compounds. In this study, the effects of five new
synthetic benzofuranone derivatives were investi-
gated on the insulin amyloid formation process.
Protein fibrillation was analyzed by thioflavin-T
fluorescence, Congo red binding, circular dichro-
ism, and electron microscopy. Despite high struc-
tural similarity, one of the five tested compounds
was observed to enhance amyloid fibrillation,
while the others inhibited the process when used
at micromolar concentrations, which could make
them interesting potential lead compounds for the
design of therapeutic antiamyloidogenic com-
pounds.
Key words: aggregation, amyloid, benzufuranone, bovine insulin,
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Amyloid structures are now believed to be a generic property of
proteins that is in principle reachable by all polypeptides (1). A
glance at the recent literature reveals that the amyloid state of
proteins that are involved in the so-called amyloidosis diseases
(i.e., abeta peptide, alpha-synuclein, and tau-protein) has been
more focused on. On the other hand, even proteins that are com-
monly thought as only 'models' of amyloid structure have also
been shown to be involved in disease states [e.g., lysozyme (2)
and insulin (3)].
Amyloid structures, characterized by cross-beta-sheets structural
elements, are suggested to possess a quasi-crystalline composition
that makes them different from amorphous aggregates which could
also be rich in beta-sheets (4). In the course of amyloid fibril forma-
tion, various stages exist, which could be typically stated as: mono-
mers, small soluble oligomers, protofibrils formed from the
assembly of smaller units, and finally mature fibrils, which, for
example in the case of the abeta peptide, could contribute to the
formation of plaques (5). While fibrils were once considered to be
toxic species, further studies have shown that in fact oligomeric
states of the protein are responsible for the cellular toxicity
observed in amyloidosis (6), and it has even been suggested that
besides an obvious therapeutic benefit derived from the inhibition
of oligomers formation, prompting the formation of mature fibrils
could also have such a potential (7).
Inhibiting the formation of amyloid structures has gained more
and more attention from multiple research groups in the recent
years. These inhibitors could be roughly divided into two groups
of peptide-based and small molecules, with the latter encom-
passing a wide range of different chemical structures [such a
variety could be for example seen in compounds tested in ref.
(7)]. As protein–protein interaction is stated to possess a 'hot
spot' component, i.e., while occurring at large surfaces, having a
smaller number of critical residues that are important for these
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interactions, the search for small molecules that would be able
to target these areas has regained strength in recent years (8).
Interestingly, these 'hot spots' have been found to be rich in
aromatic and charged residues (9), and a large number of com-
pounds tested for antiamyloidogenic activities possess also aro-
matic components, which are potentially able to interact with
these residues (7).
Different compounds have been proposed as potential antiamy-
loidogenic agents, but further investigation is needed to find
new candidates that would eventually make clinically validated
agents (10).
In this study, five novel compounds belonging to the benzofura-
none class (Scheme 1) have been tested for their effects on insu-
lin amyloid formation. Insulin is a small polypeptide of 51 amino
acids and has been suggested to form oligomers composed
predominantly of alpha-helical structures (11), reaching a flat
beta-sheet-rich state upon fibrillation (12). It is involved in the
formation of fibrils at the site of frequent insulin injection in
patients with diabetes (3) and could relatively easily be driven to
form fibrils under in vitro conditions. The effect of benzofuranone
compounds on this process has been investigated through the use
of fluorometry, circular dichroism (CD), and electron microscopy.
Four of these compounds have been shown to slow down amyloid
formation of insulin.
Methods and Materials
Bovine insulin, thioflavin-T (ThT), and Congo red (CR) were pur-
chased from Sigma (St Louis, MO, USA), and all salts and organic
solvents were from Merck (Darmstadt, Germany). The five synthetic
benzofuranone derivatives have been synthesized in the Medicinal
Chemistry Department, Tehran University of Medical Sciences.
Synthesis of benzofuranone derivatives
3(2H)-Benzofuranones, the key intermediates for the production of
the desired compounds, were prepared according to previously
described procedures (13,14). Title compounds (1–4) were prepared
by condensation of appropriate 3(2H)-benzofuranone with 5-nitrofu-
ran-2-carbaldehyde or 5-nitrothiophene-2-carbaldehyde in acetic
acid, in the presence of catalytic amount of sulfuric acid (15)
(Scheme 2), while compound 5 was prepared by a different method,
in ethanol in the presence of catalytic amount of HCl (16).
Chemistry
Melting points were determined with a Reichert-Jung hot-stage
microscope and are uncorrected. Infrared spectra were recorded
on a Nicolet Magna 550-FT spectrometer. 1H NMR (400 MHz)
spectra were measured on a Varian Unity plus 400 spectrometer
in CDCl3 with tetramethylsilane (TMS) as the internal standard,
where J (coupling constant) values are estimated in Hertz. Ele-
mental microanalyses were carried out with a Perkin-Elmer 240-C
apparatus and were within €0.4% of the theoretical values for
C, H, and N.
General procedure for the preparation of
substituted (Z)-2-(5-nitrofuran (or thiophene)-2-
ylmethylene)-3(2H)-benzofuranones (1–4)
Equimolar amounts of the appropriate substituted 3(2H)-benzofura-
none (1 mmol) and 5-nitrofuran-2-carbaldehyde (or 5-nitrothiophene-
2-carbaldehyde) in acetic acid (5 mL) and sulfuric acid (98% w ⁄w,
0.1 mL) were stirred overnight at room temperature. Then, 10 mL of
Scheme 1: Structures of the five new benzofuranone compounds.
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methanol was added and the insoluble product was filtered off and
recrystallized from methanol.
(Z)-6,7-Dimethoxy-2-(5-nitrothiophene-2-
ylmethylene)-3(2H)-benzofuranone (1)
Yield, 59%; mp 248–249 C.
1H-NMR (CDCl3): d 7.91 (d, J = 4.4 Hz, 1H), 7.53 (d, J = 8.4 Hz, 1H),
7.33 (d, J = 4.4 Hz, 1H), 6.98 (s, 1H), 6.84 (d, J = 8.4 Hz, 1H), 4.26
(s, 3H), 4.02 (s, 3H).
IR (KBr): m ( ⁄ cm) 1697 (CO), 1519, 1337 (NO2).
Anal. Calcd for C15H11NO6S: C, 54.05; H, 3.33; N, 4.20. Found: C,
53.88; H, 3.49; N, 4.06.
(Z)-6,7-Dimethoxy-2-(5-nitrofuran-2-
ylmethylene)-3(2H)-benzofuranone (2)
Yield, 50%; mp 215–216 C.
1H-NMR (CDCl3): d 7.52 (d, J = 8.4 Hz, 1H), 7.43 (d, J = 3.6 Hz, 1H),
7.13 (d, J = 3.6 Hz, 1H), 6.82 (d, J = 8.4 Hz, 1H), 6.74 (s, 1H), 4.24
(s, 3H), 4.01 (s, 3H).
IR (KBr): m ( ⁄ cm) 1709 (CO), 1519, 1358 (NO2).
Anal. Calcd for C15H11NO7: C, 56.79; H, 3.49; N, 4.42. Found: C,
56.96; H, 3.62; N, 4.33.
(Z)-6-Methoxy-2-(5-nitrothiophene-2-
ylmethylene)-3(2H)-benzofuranone (3)
Yield, 57%; mp 254–255 C.
1H-NMR (CDCl3): d 7.91 (d, J = 4.4 Hz, 1H), 7.71 (d, J = 8.4 Hz, 1H),
7.31 (d, J = 4.4 Hz, 1H), 6.96 (s, 1H), 6.85 (d, J = 2 Hz, 1H), 6.81
(dd, J = 8.4, 2 Hz, 1H), 3.97 (s, 3H).
IR (KBr): m ( ⁄ cm) 1701 (CO), 1484, 1334 (NO2).
Anal. Calcd for C14H9NO5S: C, 55.44; H, 2.99; N, 4.62. Found: C,
55.60; H, 3.17; N, 4.49.
(Z)-6-Methoxy-2-(5-nitrofuran-2-ylmethylene)-
3(2H)-benzofuranone (4)
Yield, 45%; mp 251–252 C.
1H-NMR (CDCl3): d 7.71 (d, J = 8.4 Hz, 1H), 7.43 (d, J = 4.0 Hz, 1H),
7.18 (d, J = 4.0 Hz, 1H), 6.81 (dd, J = 8.4, 2 Hz, 1H), 6.79 (s, 1H),
6.73 (d, J = 2 Hz, 1H), 3.95 (s, 3H).
IR (KBr): m ( ⁄ cm) 1700 (CO), 1463, 1350 (NO2).
Anal. Calcd for C14H9NO6: C, 58.54; H, 3.16; N, 4.88. Found: C,
58.67; H, 3.02; N, 5.03.
Protein concentration
Protein concentration was determined by absorbance measurement
at 280 nm, using an extinction coefficient of 1.0 (17).
Amyloid preparation
Bovine insulin was dissolved at 1 mg ⁄mL in 0.1 M phosphate buf-
fer of (pH 8) containing 1 mM EDTA, followed by dialysis against
the same buffer (devoid of EDTA) for 24 h. The protein solution
was then incubated at 37 C for the specified duration while
being stirred gently by Teflon magnetic bars. In another series of
test, acidic medium was used to induce amyloid formation in insu-
lin. Bovine insulin was dissolved at 1 mg ⁄mL in 50 mM glycine
(pH 2.5) and incubated at 37 C for 24 h, in agitation conditions
similar with the previous experiment. The main work is related to
the first set of conditions, and each time an experiment has been
performed in acidic conditions, this fact is explicitly mentioned in
the manuscript.
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Scheme 2: Reagents and conditions: (a) acetic acid ⁄ sulfuric acid, RT, 24 h.
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Thioflavin T binding assays
All fluorescence experiments were carried out on a Cary Ellipse Var-
ian fluorescence spectrophotometer (Mulgrave, Australia) at room
temperature. To investigate the formation of amyloid fibrils, 10 lL
of insulin samples (1 mg ⁄mL) was added to 590 lL of 13 lM ThT
solution (from 2.5 mM ThT stock solution in 10 mM sodium phos-
phate, 150 mM NaCl, pH7, passed through a 0.45 lM filter paper),
mixed completely, and incubated for 5 min. Fluorescence emission
spectra were then taken using excitation at 440 nm. The excitation
and emission slit widths were set a 5 nm (18).
Congo red binding assay
A stock of 7 mg ⁄mL CR was prepared in 5 mM potassium phos-
phate buffer containing 150 mM NaCl. Insoluble particles were
removed by filtering twice through a center-glass N4 filter and the
filtrate was diluted 2000 times with the same buffer. Ten microli-
ters of a 1 mg ⁄mL protein solution was taken at 24 h after incuba-
tion for amyloid formation and was diluted into CR solution with a
final volume of 235 lL followed by incubation at 25 C without fur-
ther stirring for at least 5 min in the dark. The absorbance spec-
trum was acquired on a Shimadzu UV-visible spectrophotometer
(Kyoto, Japan) in the region of 400–600 nm (18).
Circular dichroism
Circular dichroism spectra in the far-UV region (190–260 nm) were
obtained on an AVIV 215 spectropolarimeter (Aviv Associates, Lake-
wood, NJ, USA), using a 1-mm path cell at room temperature. Pro-
tein concentration was 0.2 mg ⁄mL.
Transmission electron microscopy (TEM)
Ten microliters of insulin samples was put on copper 400-mesh
grids, which had been covered with carbon coated formvar films.
After 2 min, excess fluid was drawn out using a paper filter and
1% uranyl acetate added. After another 2 min, excess dye was
removed. Finally, the grids were viewed with a CEM 902A Zeiss
microscope (Oberkochen, Germany).
Monitoring the effect of benzofuranone
derivatives
The five different synthetic compounds were diluted into DMSO
while keeping the final concentration of the solvent at 12%. Con-
centrations of insulin and the five synthetic compounds were kept
at 1 mg ⁄mL and 4 lM, respectively. To drive insulin toward amyloid
fibril formation, the protein was incubated at pH 8.0 and 37 C.
Formation of amyloid fibrils in the presence and absence of these
compounds was then verified through the above-mentioned specific
methods of amyloid detection; DMSO alone had no effect on insulin
fibril formation.
Docking experiment
Docking was performed using the graphical interface MGL Tools
1.5.1 (The Molecular Graphics Laboratory, Scripps Research Insti-
tute) for Autodock. The executable file vina was used for the actual
A
B
Figure 1: (A) Fluorescence spectra of ThT binding assay for
native insulin (–), insulin after 24-h incubation under amyloidogenic
conditions in the absence of any additive (e) and in the presence of
compounds 1 (h), 2 (d),3 (m), 4 (·), and 5 (j). (B) Values obtained
from measurement of absorbance at 520 nm, as an indicator of inter-
action with Congo red (CR). Measured samples include CR control
(the dye alone), insulin incubated under amyloidogenic conditions
without additives, and in the presence of compounds 1–5.
Figure 2: Far-UV circular dichroism spectra of insulin after 24-h
incubation under amyloidogenic conditions in the absence of any
additive (e), and in the presence of compounds 1 (h), 2 (d), 3
(m), 4 (·), and 5 (j). Native insulin spectrum (–) is shown in the
inset. [Mol.Ellp.: molar ellipticity (degree cm2 ⁄ dmol)].
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docking using an exhaustiveness of 20 (19). Blind docking method
was used with grid boxes encompassing bovine insulin structure
from the 1EV3.pdb file. pKa prediction module of moe 2009.10
(Chemical Computing Group Inc., Montreal, QC, Canada) was used
to achieve a probable protonation state of the protein at pH 8 and
2.5. Both protonation states of the protein were used in the docking
experiment. Visualization of best-obtained docking poses and prepa-
ration of image were carried out using moe 2009.10.
Results and Discussion
Bovine insulin could form hexamers that are connected to each
other via two zinc ions complexed with histidine residues. Insulin
monomers are composed of two chains (A and B), which are
linked together by two disulfide bonds. Dissociation of hexamers
increases insulin propensity to form amyloid structures. Insulin
amyloid units are thus formed from monomeric insulin that is
thought to remain intact with regard to its disulfide bonds (20).
In this study, insulin samples were dissolved in phosphate buffer
(pH 8) containing EDTA, to facilitate monomer formation. Dialysis
against the same buffer was subsequently carried out to remove
EDTA and zinc.
Formation of amyloid fibrils was verified through specific methods
of amyloid detection. Spectrophotometric methods included ThT
binding assay which showed increased fluorescence in the presence
of the protein incubated in the amyoidogenic conditions (37 C and
pH 8) in the absence of any additives, as well as CR test, in which
increase in absorbance was observed in the wavelength range of
400–600 nm, with a red shift from 490 to 520 nm (Figures S1 and
S2). Absorbance at 520 nm was used as an indicator of amyloid
structures formation (Figure 1). Addition of four of five synthetic
compounds (compounds 1–5) at 4 lM concentration inhibited amy-
loid structure formation, as monitored by a decrease in ThT fluores-
cence intensity and CR absorbance at 520 nm. On the other hand,
No additive 1
2 3
4 5
Figure 3: Transmission electron
microscopy images obtained from
insulin after 24-h incubation under
amyloidogenic conditions in the
absence of any additive (labeled
'no additive') and presence of
compounds no 1–5, labeled 1–5.
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one of the synthetic compounds (compound 5) appeared to enhance
the process (Figure 1). It should be mentioned that the process of
amyloid formation was first studied in the absence of additives,
where ThT and CR spectra were taken at intervals during a 24-h
period, and mature fibrils were detected at this time.
Insulin being an all-alpha-protein, a far-UV spectrum is obtained
from its native structure with typical minima at 208 and 222 nm,
characteristics of a-helical structures (Figure 2, inset). Utilizing the
amyloidogenic condition and in the absence of any additives, this
spectrum is changed to one with a deep minimum peak at 215 nm
that is expected for b-sheet-containing structures (Figure S3). Incu-
bation of insulin with compounds no. 1–4 (at 4 lM concentration)
resulted in an increase in the molar ellipticity (Figure 2). On the
other hand, compound 5 was again shown to have an enhancing
effect on this process: its presence resulted in the appearance of a
deeper peak at 215 nm (Figure 2); b-structures were clearly detect-
able after 4–5 h of incubation of the protein (results not shown).
As a final proof, TEM was performed. Samples of the protein were
drawn after 24 h incubation for which the corresponding TEM
images are shown in Figure 3. In the absence of any additives,
clearly observable mature fibrils were detected. Upon addition of
four of five synthetic compounds at 4 lM concentration, amyloid
fibrillation was considerably inhibited by compound no. 3, to a les-
ser degree by compounds no. 1, 2, and 4, and noticeably enhanced
by compound no. 5. To get more information on the antiamyloido-
genic capacity of the compounds, acidic amyloidogenic conditions
were used. Here too, all four effective compounds were able to
prevent fibril formation to some extent, with compounds no. 4 and
3 acting more effectively as compared to no. 1 and 2. These
results were obtained by inspecting TEM images of samples, after
a first assessment by CR spectra (results not shown).
Preserving the native structure of a protein would be an ideal way
to prevent formation of amyloid structures. In this case, however, it
seems that all the effective compounds are capable of interfering
with beta-sheets assembly as suggested by CD spectra. As seen in
TEM images, the amount of fibrils varies depending on the com-
pound used.
Introducing a compound in the amyloidogenic medium that would
prevent the formation of beta-sheets by the target protein is one of
the early proposed therapeutic approaches for the prevention of ab-
eta amyloid neurotoxicity. This idea resulted in the design of a
number of synthetic peptides that were shown to be effective in
this regard (21), from which iAb5p is probably the most known.
Low stability under in vivo conditions and the need for peptides to
be injected have always been a major problem in the use of this
class of molecules as drugs. This is why a search toward smaller
molecules possessing beta-sheet breaking properties may have
great practical potential.
To our knowledge, there has not been any report on antiamyloido-
genic property of compounds containing benzofuranone; however,
different benzofurane derivatives have been studied in this regard.
One of the first studies of this kind relates to some bulky benzofu-
rane derivatives as inhibitors of abeta peptide fibril formation
A
B
C
Figure 4: Graphical representation of the docking experiment
results: (A) two major binding sites that were found by blind dock-
ing, the main putative binding site is chain B, and the second site
is the phenol binding pocket; (B) superimposition of the best poses
obtained for the five ligands in chain B, with acidic protonation
state of the protein; (C) putative interactions of the ligands with
nearby amino acids in chain B.
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thought to have specific interaction with this protein. Smaller ben-
zofuranes which could be comparable to the present compounds
related to their size were found to have much higher IC50 toward
abeta fibril formation (more than 1 mM) than bulkier derivatives
which possessed extra aromatic branching in their structure (22).
It could be suggested that these compounds were also acting by
a beta-sheet-breaking mechanism. One of the smaller benzofurane
containing structure (SKF-63058) has also been recently used as
the antifibrillation component of a hybrid ligand designed to act
simultaneously at multiple targets including the cholinesterase
enzyme (23). Dibenzofuran-4,6-dicarboxylic acid derivatives have
also been shown to strongly inhibit transthyretin amyloid forma-
tion. These structures are bulkier and contain more aromatic com-
ponents than the benzofuranones tested here, besides the fact
that in the case of transthyretin, these compounds, as well as
many other small molecules, have been found to be able to bind
to a specific cavity of the protein, namely the thyroxine binding
site (24). Another series of compounds that could be more closely
compared with the ligands are aminostyrylbenzofuran derivatives,
which were recently studied on abeta peptides fibrillation, with
the use of a ThT test. In this study, the most effective compounds
were found to bear one methoxy group on their benzofurane moi-
ety (25).
A preliminary structure–function relationship could be formulated
based on the results of the current study, where it was observed
that compounds no. 3 and 4, possessing only one methoxy group
on the benzofuranone core, acted more effectively than their
counterparts which contain two methoxy groups on the same moi-
ety. As mentioned above, this was observed to be the case for
two of the potent aminostyrylbenzofuran derivatives studied on
the abeta peptide (25), a point that brings again the possibility of
a generic effect of these compounds, i.e., an inhibitory action
toward beta-sheets. Compounds no. 3 and 4 are also effective in
a similar manner toward insulin fibrils formed under acidic condi-
tions, i.e., under a different set of amyloidogenic conditions. It
could be suggested that the common point of these two experi-
ment would be the beta-component of these amyloid structures.
On the other hand, thiophene derivatives work better than furane
containing derivatives, because compounds no. 1 and 3 are both
more effective than their counterparts no. 2 and 4. It is interest-
ing to note that compound no. 5 lacks any substitution on the
benzofuranone core, but a rational explanation for the reverse
effect of this ligand on fibrillation is not straightforward. There
has been a report about the unawaited effect of small aromatic
compounds that enhance amyloid formation in insulin (in contrast
with compounds containing multiple rings). This effect is especially
remarkable for benzene and phenol which result in the formation
of more compact fibrils (26). Thus, the unsubstituted benzene com-
ponent of ligand no. 5 could be suggested to be the reason for
its different effect.
As a matter of fact, the use of compounds that increase fibrillation
has been recently proposed as a possible alternative to compounds
that would prevent the starting metamorphosis of the proteins
toward fibril formation (7). However, this concept undoubtfully
needs more evidence before being considered as a novel line for
therapeutics research. Compound no. 5 and similar compounds
could be of use in this regard, for example, for testing their
cytotoxicity with the use of in vitro systems.
A docking experiment was performed to provide an insight into a
possible binding mode of the compounds with insulin. A native
structure of human insulin crystallized with cresol was used in this
experiment. Interestingly, the compounds were found to bind insu-
lin in an extended conformation (Figure 4A), which could suggest
them to be suitable for binding to the subsequently formed beta-
sheets. The whole protein structure was given to the docking pro-
gram, to find putative binding sites, and interestingly, only two
sites were found, in a total of 100 poses for all the ligands with
the best one being the B-chain of insulin, which has the potential
to form amyloid structure independently (Figure 4B). The second
location is the phenol binding pocket, where phenol molecules
interact, a process that is known to afford stabilization of the pro-
tein structure (27). In both protonation states of the protein (pH 8
and 2.5), a similar binding position was obtained for the ligands.
In Figure 4C, best poses of all five ligands have been superim-
posed in the B-chain location and in the acidic protonation state.
As shown there, the main interacting residues are His5 and Tyr26.
Putative hydrogen bonds could be formed with the side chain of
Tyr26 by all the ligands. However, the possible hydrogen bonds
with His5 would be only made by compounds bearing a 7-methoxy
group (i.e., compounds no. 1 and 2). The other potential interaction
would be an arene–cation interaction between the aryl groups of
the ligands and His5. The potential hydrogen binding with His5
would be thus the most prominent difference between the poten-
tial interactions of the effective ligands and should have some del-
eterious effect on the inhibition process. It should be pointed out
that this is only a first theoretical attempt to explain a very com-
plex process which involves many intermediate structures of insulin
and a wide range of potential interactions between the ligands
and these structures.
Results presented in the present communication may be considered
as a preliminary report on the beneficial effect of benzofuranone
derivatives as inhibitors of amyloid fibrillation. The present class of
compounds possess the characteristics of being relatively simple to
derivatize and small enough to fit the drug-like requirements. As
these could have a beta-sheet breaker property, they also present
an interesting new series to be explored in that direction.
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